Rivaroxaban Once-Daily vs. Dose-Adjusted Vitamin K Antagonist on Biomarkers in Acute Decompensated Heart Failure and Atrial Fibrillation (ROAD HF-AF): Rationale and Design of an Investigator-Initiated Multicenter Randomized Prospective Open-Labeled Pilot Clinical Study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Cho, Iksung | - |
dc.contributor.author | Oh, Jaewon | - |
dc.contributor.author | Kim, In-Cheol | - |
dc.contributor.author | Chung, Hyemoon | - |
dc.contributor.author | Lee, Jung-Hee | - |
dc.contributor.author | Kim, Hyue Mee | - |
dc.contributor.author | Byun, Young Sup | - |
dc.contributor.author | Yoo, Byung-Su | - |
dc.contributor.author | Choi, Eui-Young | - |
dc.contributor.author | Chung, Wook-Jin | - |
dc.contributor.author | Pyun, Wook Bum | - |
dc.contributor.author | Kang, Seok-Min | - |
dc.date.accessioned | 2023-03-08T09:21:10Z | - |
dc.date.available | 2023-03-08T09:21:10Z | - |
dc.date.issued | 2022-01 | - |
dc.identifier.issn | 2297-055X | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/61755 | - |
dc.description.abstract | Background: Clinical trials of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with chronic heart failure and atrial fibrillation (AF) have demonstrated reduced risks of stroke and bleeding compared with vitamin K antagonists (VKAs). Here, we aim to assess the clinical efficacy and safety of rivaroxaban, a NOAC, compared with warfarin, a VKA, and the effects of rivaroxaban on cardiovascular biomarkers in patients with acute decompensated heart failure (ADHF) with reduced ejection fraction (& LE;40%) and AF.Methods: Rivaroxaban Once-daily vs. dose-adjusted vitamin K antagonist on biomarkers in Acute Decompensated Heart Failure and Atrial Fibrillation (ROAD HF-AF) is a randomized, open-labeled, controlled, prospective, multicenter pilot study designed to assess cardiovascular biomarkers and the safety of rivaroxaban (20 or 15 mg in patients with creatinine clearance 30-49 mL/min per day) compared with VKA (target international normalized range: 2-3) in 150 patients hospitalized with ADHF and AF. The primary endpoint is the change in circulating high-sensitivity cardiac troponin (hsTn) during hospitalization. The secondary endpoints are bleeding, hospital stay duration, in-hospital mortality, and changes in cardiovascular, renal, and thrombosis biomarkers. Patients will be followed for 180 days.Conclusion: We hypothesize that rivaroxaban will reduce myocardial injury and hemodynamic stress, as reflected by the biomarker status, within 72 h in patients with ADHF and AF, compared with VKA. We hope to facilitate future biomarker-based, large-scale outcome trials using NOACs in patients with ADHF and AF, based on the results of this multicenter, randomized, controlled study. | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | FRONTIERS MEDIA SA | - |
dc.title | Rivaroxaban Once-Daily vs. Dose-Adjusted Vitamin K Antagonist on Biomarkers in Acute Decompensated Heart Failure and Atrial Fibrillation (ROAD HF-AF): Rationale and Design of an Investigator-Initiated Multicenter Randomized Prospective Open-Labeled Pilot Clinical Study | - |
dc.type | Article | - |
dc.identifier.doi | 10.3389/fcvm.2021.765081 | - |
dc.identifier.bibliographicCitation | FRONTIERS IN CARDIOVASCULAR MEDICINE, v.8 | - |
dc.description.isOpenAccess | Y | - |
dc.identifier.wosid | 000748027600001 | - |
dc.identifier.scopusid | 2-s2.0-85175554101 | - |
dc.citation.title | FRONTIERS IN CARDIOVASCULAR MEDICINE | - |
dc.citation.volume | 8 | - |
dc.type.docType | Article | - |
dc.publisher.location | 스위스 | - |
dc.subject.keywordAuthor | rivaroxaban | - |
dc.subject.keywordAuthor | acute decompensated heart failure | - |
dc.subject.keywordAuthor | atrial fibrillation | - |
dc.subject.keywordAuthor | vitamin K antagonist (VKA) | - |
dc.subject.keywordAuthor | biomarker | - |
dc.subject.keywordPlus | 2016 ESC GUIDELINES | - |
dc.subject.keywordPlus | CARDIAC TROPONIN | - |
dc.subject.keywordPlus | ISCHEMIC-STROKE | - |
dc.subject.keywordPlus | RELAX-AHF | - |
dc.subject.keywordPlus | SERELAXIN | - |
dc.subject.keywordPlus | MECHANISMS | - |
dc.subject.keywordPlus | MANAGEMENT | - |
dc.subject.keywordPlus | ELEVATION | - |
dc.subject.keywordPlus | DIAGNOSIS | - |
dc.subject.keywordPlus | INSIGHTS | - |
dc.relation.journalResearchArea | Cardiovascular System & Cardiology | - |
dc.relation.journalWebOfScienceCategory | Cardiac & Cardiovascular Systems | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.